Track topics on Twitter Track topics that are important to you
AUT00063 develpoed by Autifony Therapeutics, is a novel, orally active small molecule designed to selectively modulate Kv3 potassium channels, which are important in central auditory processing. Preclinical studies have shown that AUT00063 has the potential to reduce symptoms of age-related hearing loss and tinnitus, and may also help to prevent hearing loss caused by noise trauma. Safety and toxicology studies support the clinical development of AUT00063, and suggest that the drug will be safe and well tolerated in humans.
Stevenage, UK - 15 March 2017 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central ne...
PureTech Health plc (“PureTech” or the “Company”, LSE: PRTC), a cross-disciplinary biopharmaceutical company, today announced the appointment of Atul Pande, M.D., as the C...
Demonstrated dose dependent changes in Mismatch Negativity latency in healthy volunteers; Phase Ib Ketamine challenge study initiated in Manchester London, UK - 10th January 2017 - Autifony Th...
The study medicine is a potential future treatment for schizophrenia, an illness that affects the way that people think, feel or behave. It is not clear what causes schizophrenia, but it's...
Hearing, auditory perception, or audition is the ability to perceive sound by detecting vibrations, changes in the pressure of the surrounding medium through time, through an organ such as the ear. Sound may be heard through solid, liquid, or gaseous mat...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...